Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. Fortunately, with our new style score system we have identified the key statistics to pay close attention to and thus which stocks might be the best for momentum investors in the near term.
This method discovered several great candidates for momentum-oriented investors, but today let's focus on PTC Therapeutics, Inc.PTCT as this stock is looking especially impressive right now. And while there are numerous ways in which this company could be a great choice, we have highlighted three of the most vital reasons for PTCT's status as a solid momentum stock below:
Short Term Price Change for PTC Therapeutics
A great place to look for finding momentum stocks is by inspecting short term price activity. This can help to reflect the current interest in a stock and if buyers or sellers have the upper hand right now. It is especially useful to compare it to the industry as this can help investors pinpoint the top companies in a particular area.
With a one week price change of 0.05% compared to an industry average of 0%, PTCT is certainly well-positioned in this regard. The stock is also looking quite well from a longer time frame too, as the four week price change compares favorably with the industry at large.
Longer Term Price Change for PTC Therapeutics
While any stock can see a spike in price, it takes a real winner to consistently outperform the market. That is why looking at longer term price metrics-such as performance over the past three months or year-- and comparing these to an industry at large can be very useful.
And in the case of PTCT, the results are quite impressive. The company has beaten the industry at large over the past 12 weeks by a margin of 94.5% to -1.7%, while it has also outperformed when looking at the past year, putting up a gain of 285.7%. Clearly, PTCT is riding a bit of a hot streak and is worth a closer look by investors.
PTC Therapeutics, Inc. Price
PTC Therapeutics, Inc. Price | PTC Therapeutics, Inc. Quote
PTCT Earnings Estimate Revisions Moving in the Right Direction
While the great momentum factors outlined in the preceding paragraphs might be enough for some investors, we should also take into account broad earnings estimate revision trends. A nice path here can really help to show us a promising stock, and we have actually been seeing that with PTCT as of late.
Over the past two months, two earnings estimates have gone higher compared to none lower for the full year, while we are also seeing that one estimate has moved upwards with no downward revision for the next year time frame. These revisions have helped to boost the consensus estimate, as two months ago, PTCT was expected to post a loss of $2.50 per share for the full year, though today it looks to have a loss of 70 cents for the full year, representing a solid increase which is something that should be welcome news to would-be investors.
Given these factors, investors shouldn't be surprised to note that we have PTCT as a security with a Zacks Rank #2 (Buy) and a Momentum Score of A. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
So if you are looking for a fresh pick that has potential to move in the right direction, definitely keep PTCT on your short list as this looks be a stock that is very well-positioned to soar in the near term.
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Download it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportPTC Therapeutics, Inc. (PTCT): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research